Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuxuening injection
- Development stage
- Phase 4
- Lead developer
- Peking University Third Hospital
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Shuxuening injection (SXNI) is a traditional Chinese medicine (TCM) botanical extract derived from *Ginkgo biloba* leaves, widely utilized in China for the treatment of cardiovascular and cerebrovascular diseases. In the context of acute ischemic stroke, it functions as a multi-target neuroprotective agent. Its pharmacological profile includes the inhibition of platelet-activating factor (PAF) receptors, regulation of neurotrophin signaling pathways (specifically brain-derived neurotrophic factor/Trk signaling), and down-regulation of G-CSF-mediated granulocyte adhesion and diapedesis. Clinical evaluation, including Phase 4 trials led by Peking University Third Hospital, has demonstrated its efficacy in improving neurological deficits and functional outcomes when used as an adjunct to conventional stroke therapies such as aspirin or thrombolysis.
- Brand names
- Shuxuening
- Other names
- Shuxinin injectionGinkgo biloba extract injection
02
Targets
PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on Shuxuening injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shuxuening injection.